Pharma Focus Asia

LianBio Announces Clinical Supply Agreement with AstraZeneca in China

Thursday, July 13, 2023

LianBio announced a clinical supply agreement with AstraZeneca in China. 

The agreement aims to evaluate the safety and efficacy of BBP-398, an investigational SHP2 inhibitor developed by LianBio and BridgeBio, in combination with AstraZeneca's osimertinib, an epidermal growth factor receptor (EGFR) inhibitor.

LianBio and BridgeBio have a strategic collaboration for the clinical development and commercialisation of BBP-398 in combination with various agents in solid tumours, including non-small cell lung cancer, colourectal cancer, and pancreatic cancer. This collaboration covers mainland China and other Asian markets.

BBP-398 is a SHP2 inhibitor designed to target difficult-to-treat cancers. SHP2 is a protein-tyrosine phosphatase that plays a role in regulating cellular proliferation and survival through its connections with growth factor, cytokine, and integrin signalling, as well as the downstream RAS/ERK MAPK pathway.

In China, a significant percentage of NSCLC patients have EGFR mutations. While EGFR inhibitors are commonly used in their treatment, many patients eventually develop resistance to these therapies. BBP-398, as a differentiated SHP2 inhibitor, has the potential to restore sensitivity to EGFR inhibitors when used in combination therapy.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024